Grover disease shows Type 2 immune activation and improves with dupilumab

Molecular profiling on 31 biopsies of Grover's Disease (GD) shows increased expression of IL13 (Th2) to be a hallmark of GD. In a supportive retrospective series of 9 patients with treatment refractory GD all improve with dupilumab. This work helps establish GD as a Type 2 immune disorder.

Saved in:
Bibliographic Details
Published in:British journal of dermatology (1951) 2025-01
Main Authors: Murphy, Michael J, Junejo, Muhammad H, Rufin, Okeroghene, Cohen, Jeffrey M, Nelson, Caroline A, Damsky, William
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Molecular profiling on 31 biopsies of Grover's Disease (GD) shows increased expression of IL13 (Th2) to be a hallmark of GD. In a supportive retrospective series of 9 patients with treatment refractory GD all improve with dupilumab. This work helps establish GD as a Type 2 immune disorder.
ISSN:0007-0963
1365-2133
1365-2133
DOI:10.1093/bjd/ljaf005